Skip to content

VATS or Intrapleural Enzymatic Therapy for patientS with empyema (the VIETS trial)

Status
Not yet recruiting
Phases
Phase 4
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2026-526289-25-00
Enrollment
164
Registered
2026-07-24
Start date
Unknown
Completion date
Unknown
Last updated
2026-07-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parapneumonic pleural infection/pleural empyema

Brief summary

Length of hospital stay (LOS) during the first 30 days.

Detailed description

Measures related to treatment (duration of chest tube drainage, delayed discharge days, re-intervention and re-admission rates, morbidity, mortality, type and duration of antibiotic treatment and pain medication)., Patient reported outcomes (pain, health related quality of life, limitations in daily activities, return to work)., Economic evaluation (healthcare costs, costs of patient, costs of productivity loss, health related quality of life).

Interventions

DRUGActilyse 20 mg
DRUGpoeder en oplosmiddel voor oplossing voor injectie en infusie
DRUGPulmozyme 2500 E/2
DRUG5 ml
DRUGverneveloplossing

Sponsors

Amsterdam UMC Stichting
Lead SponsorOTHER

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Design outcomes

Primary

MeasureTime frame
Length of hospital stay (LOS) during the first 30 days.

Secondary

MeasureTime frame
Measures related to treatment (duration of chest tube drainage, delayed discharge days, re-intervention and re-admission rates, morbidity, mortality, type and duration of antibiotic treatment and pain medication)., Patient reported outcomes (pain, health related quality of life, limitations in daily activities, return to work)., Economic evaluation (healthcare costs, costs of patient, costs of productivity loss, health related quality of life).

Outcome results

None listed

Source: EU CTIS · Data processed: Jul 25, 2026